Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-014775
Filing Date
2024-11-07
Accepted
2024-11-07 09:25:32
Documents
64
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q xlo-20240930x10q.htm   iXBRL 10-Q 1888126
2 EX-31.1 xlo-20240930xex31d1.htm EX-31.1 13370
3 EX-31.2 xlo-20240930xex31d2.htm EX-31.2 13273
4 EX-32.1 xlo-20240930xex32d1.htm EX-32.1 7889
  Complete submission text file 0001558370-24-014775.txt   6321615

Data Files

Seq Description Document Type Size
5 EX-101.SCH xlo-20240930.xsd EX-101.SCH 43230
6 EX-101.CAL xlo-20240930_cal.xml EX-101.CAL 36594
7 EX-101.DEF xlo-20240930_def.xml EX-101.DEF 216620
8 EX-101.LAB xlo-20240930_lab.xml EX-101.LAB 380978
9 EX-101.PRE xlo-20240930_pre.xml EX-101.PRE 334006
67 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20240930x10q_htm.xml XML 730020
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40925 | Film No.: 241433523
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)